Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms The IDA2 study
- 09 Feb 2022 This trial has been discontinued (End Date: 01 Jan 2022), according to European Clinical Trials Database record.
- 13 Oct 2016 New trial record